Malaysia faces a public health emergency with cardio-renal-metabolic diseases—encompassing cardiovascular conditions, kidney disease, and diabetes—rising at an unsettling pace and increasingly striking Malaysians in overlapping patterns. The National Cancer Society Malaysia has launched an urgent appeal for the government to adopt a coordinated national screening strategy, warning that nearly nine in ten Malaysians now carry multiple risk factors for these interconnected conditions simultaneously. This clustering of diseases represents a fundamental shift in how chronic illness manifests in the Malaysian population, demanding a similarly transformed approach to prevention and care.
The severity of the problem became evident through the NCSM-Boehringer Ingelheim Saring@Komuniti Project, which screened 5,000 residents across underserved areas of the Klang Valley with support from the Ministry of Health. The findings paint a troubling picture of hidden disease burden: 41.3 per cent of participants were classified as obese, while a further 28.8 per cent were overweight. On the metabolic front, 34.5 per cent had pre-diabetes and 35.1 per cent had already developed full diabetes, indicating that blood sugar disorders have achieved alarming prevalence in these communities. Most strikingly, 97.8 per cent of all participants exhibited at least one cardio-renal-metabolic risk factor, suggesting that disease-free individuals in these populations are now the exception rather than the norm.
The trajectory of cardio-renal-metabolic conditions in Malaysia has been consistently upward for years, creating mounting pressure on both patients and healthcare infrastructure. Chronic kidney disease alone demonstrates this troubling trend: prevalence jumped from 9.1 per cent in 2011 to 15.5 per cent by 2019. The demand for dialysis services has grown even more dramatically, with the number of Malaysians requiring dialysis more than tripling over the past two decades. These statistics suggest that kidney disease is not merely becoming more common but is reaching advanced stages in greater numbers, reflecting both aging populations and the lingering effects of uncontrolled diabetes and hypertension across the country.
What makes these conditions particularly concerning is their interconnected nature. Cardio-renal-metabolic diseases do not exist in isolation; rather, they share common underlying causes and actively accelerate each other's progression. A person with diabetes faces elevated risk of both heart disease and kidney failure. Hypertension damages blood vessels throughout the body, harming the heart, kidneys, and metabolic function simultaneously. This biological reality has profound implications for how Malaysia's healthcare system should be restructured. The current fragmented approach, treating heart disease in cardiology clinics, kidney disease in nephrology departments, and diabetes in endocrinology services, creates dangerous blind spots where overlapping risks go unrecognised and patients fall through gaps in the referral system.
The policy briefs launched by NCSM identify a critical systemic failure: Malaysia's existing healthcare framework emphasises treating individual diseases separately, causing clinicians to miss opportunities to detect and address interconnected risks. When a patient presents with one condition—say, high blood pressure—they may not receive comprehensive screening for the kidney and metabolic complications that often accompany it. This siloed approach means that by the time kidney disease or diabetes is diagnosed, significant irreversible damage may already have occurred. The NCSM advocates for embedding standardised cardio-renal-metabolic risk assessments into all routine health checks, ensuring that no patient undergoes screening without evaluation across the full spectrum of interconnected risks.
Equally concerning is the fragmentation that occurs after screening itself. Many Malaysians receive abnormal screening results but never receive appropriate follow-up care or timely intervention. Referral pathways between primary care and specialist services remain inconsistent and inefficient. Patients who should move seamlessly from screening to diagnosis to treatment encounter barriers that delay or prevent their access to necessary care. This discontinuity transforms screening programmes from life-saving tools into frustrating dead ends for vulnerable populations. Strengthening the care continuum—ensuring that screening findings trigger coordinated action rather than administrative disappearance—has become essential.
The Klang Valley screening project deliberately targeted underserved communities, a methodological choice that illuminates disparities in disease burden. These populations often have less regular access to healthcare, delayed diagnosis, and fewer resources for managing chronic conditions. The fact that such high proportions exhibited multiple risk factors underscores how cardio-renal-metabolic disease has become concentrated among Malaysia's most vulnerable residents. A truly national screening strategy must ensure equitable reach, preventing these conditions from becoming markers of socioeconomic inequality across the country.
Implementing the NCSM's recommendations would require coordination across multiple levels of the Malaysian healthcare system. Primary care practitioners would need training and resources to conduct comprehensive cardio-renal-metabolic assessments rather than fragmented disease-specific checks. Specialist services would need to develop coordinated care protocols that address the interconnected nature of these conditions. Data systems would need to be integrated so that screening results, diagnostic findings, and treatment responses can be tracked across different service providers. These are substantial organisational changes, but the cost of inaction—measured in dialysis patients, heart attack survivors, and premature deaths—appears far greater.
Dr Murallitharan Munisamy, Managing Director of NCSM, articulated the philosophical shift required: Malaysia must transition from managing individual diseases separately to addressing cardiovascular, kidney, and metabolic health as a connected continuum. This reframing acknowledges biological reality and organisational necessity. The opportunity exists for Malaysia to become a regional leader in integrated cardio-renal-metabolic screening and management, moving beyond the fragmented approaches still dominant in many developed nations. Early detection alone proves insufficient without matched coordinated follow-up and sustained long-term care, meaning the national strategy must extend from screening through diagnosis to ongoing disease management and prevention of progression.
The role of industry partners like Boehringer Ingelheim in supporting such initiatives reflects broader recognition that cardio-renal-metabolic disease represents a global health crisis requiring collaborative solutions. While pharmaceutical companies have commercial interests, their epidemiological insights and capacity to fund research contribute valuable resources to public health advocacy. The NCSM's partnership with both government and industry to develop evidence-based policy briefs demonstrates how diverse stakeholders can align around solutions to pressing health challenges.
Looking forward, Malaysia's capacity to implement a national cardio-renal-metabolic screening strategy will determine whether the rising burden of these diseases can be arrested or whether Malaysians will continue to experience the human costs of delayed diagnosis and fragmented care. The findings from the Klang Valley project provide compelling evidence that the current system is failing ordinary Malaysians. The policy briefs offer a roadmap. What remains is the political and bureaucratic will to execute a transformation that reorients the entire healthcare delivery system around how diseases actually cluster and interconnect in the real world, rather than around the organisational convenience of separate specialty silos.
